The safety of oncolytic viruses, such as conditionally replicative adenoviruses (CRAds), has been validated in clinical trials for cancer therapy. Their antitumor efficacy is limited by the presence of preexisting neutralizing antibodies (NAbs). Mesenchymal stem cells (MSCs) are attractive as a cellular vehicle to carry antitumor agents, not only because they are easily obtained and expanded to great numbers in vitro, but also because of their ability to migrate and engraft to tumors. MSCs expanded under hypoxic conditions decrease in replicative senescence and increase in proliferation capacity and differentiation potentials. However it remains to be clarified whether these hypoxic MSCs also are good carriers for the delivery of CRAds to tumor cells in the presence of NAbs. This study firstly demonstrated hypoxic MSCs with an increased ability to migrate toward tumors through the upregulation of chemokine receptors, such as CXCR4 and CX3CR1. It is then demonstrated that hypoxic MSCs has the capacity to carry CRAds, without inducing apoptosis, for up to one week. Using an in vitro coculture with human colon cancer cells and with intraperitoneally (i.p.) and subcutaneously (s.c.) developed human colon cancer xenografts, it is demonstrated that hypoxic MSCs are able to protect CRAds from attack by NAbs, thereby successfully delivering them to the target tumor cells. These results show that hypoxic MSCs can serve as cell carriers for CRAds and may help to develop new strategies against cancer.
INTRODUCTION
Oncolytic viruses are replication-competent viruses that, after genetic modification, specifically replicate in tumor cells, rather than in normal cells, thereby causing tumor-specific cytolyses. 1 In this group, conditionally replicative adenoviruses (CRAds) have recently been used in preclinical studies and clinical trials to treat a broad range of cancers. 2 Although the safety of CRAds for cancer therapy has been verified in early-phase clinical trials, 3, 4 their antitumor efficacy has not been well documented. In this regard, systemic barriers, such as complement proteins, 5, 6 uptake by the reticuloendothelial system 7, 8 and circulating antibodies 5,9-11 limit the efficacy of the delivery of viruses to the tumor site and the transduction of the tumor cells. Of these, preexisting neutralizing antibodies (NAbs) are likely to be the major obstacle to therapy, as they mediate a long-lasting state of immunity to repeated infection. 12 Because of these obstacles, high viral doses must be used, in order to improve antitumor efficacy, which can result in toxicity. One strategy to enhance the viral delivery is the use of vehicles that have endogenous tumor-targeting ability. To this aim, autologous cell types, such as irradiated cancer cells, 13, 14 activated T cells, 15, 16 dendritic cells 17, 18 and mesenchymal stem cells (MSCs), [19] [20] [21] [22] have all been studied as potential vehicles for delivery of viruses. Notably, some of these methods are limited by prolonged cell preparation, because of the specificity of the processes required. For example, therapy using immune cells as carriers must be made using cells from each individual, rather than cells from an allogeneic donor, which results in delayed therapy.
MSCs are attractive as cell vehicles for carrying antitumor agents not only because they are easily obtained and expanded to great numbers in vitro but also because of their ability to migrate and engraft to tumors. 23 MSCs possess immunosuppressive properties and can be infused with allogeneic recipients, for therapeutic purposes, without severely adverse effects. 24 We have demonstrated the advantages of a hypoxic culture on human MSCs, including the inhibition of replicative senescence, 25 an increase in proliferation capacity and differentiation potentials, [26] [27] [28] the enhancement of stemness gene expression 26 and an increased ability to engraft via the upregulation of chemokine receptors. 29 This study firstly demonstrates that hypoxic culture increases the ability of MSCs to target tumor sites. These hypoxic MSCs protect CRAds from attack by preexisting NAbs and successfully deliver CRAds to tumor cells, both in vitro and in vivo. These results suggest that hypoxic MSCs are an ideal cell-carrier system for the delivery of CRAds.
MATERIALS AND METHODS

Cell culture and virus
Human primary MSCs from bone marrow were prepared as described previously. 30 The cells were seeded at 50 cells per cm 2 and grown in a-minimal essential medium (Gibco, Gaithersburg, MD, USA), supplemented with 16.6% fetal bovine serum (Gibco), 100 U ml À 1 penicillin, 100 mg ml À 1 streptomycin and 2 mM L-glutamine. For the 1 hypoxic culture, MSCs were maintained as previously described. 25 The MSCs were cultured in a gas mixture of 94% N 2 , 5% CO 2 and 1% O 2 . To maintain the hypoxic gas mixture, an incubator with two air sensors, one for CO 2 and the other for O 2 , was used. The O 2 concentration was achieved and maintained via the delivery of N 2 from a tank containing pure N 2 . When the percentage of O 2 exceeded the desired level, N 2 gas was automatically injected into the system, to displace the excess O 2 . The passage number of MSCs used in this study was not more than five. Human colon cancer cell line HT29 was obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and grown in Dulbecco's modified Eagle medium (Gibco). The medium was changed twice a week. CRAd encoded with enhanced green fluorescent protein (CRAd-EGFP) (PS1217L), a conditionally replicating adenovirus with E1B-55KD deletion, was kindly provided by Dr M-J Chen of Mackay Memorial Hospital, Taipei. 31 
Flow cytometry
To analyze the infection efficiency of the adenovirus, the MSCs were plated at 2 Â 10 5 per 10-cm dish. After 24 h, the MSCs were washed with phosphate-buffered saline (PBS) and infected with CRAd-EGFP at a multiplication of infection (MOI) of 1000 vp per cell, in serum free a-minimal essential medium, for 1.5 h at 37 1C, and then an equal volume of growth medium was added. After 24 h of infection, the medium was replaced with fresh culture medium, containing 10% fetal bovine serum. After 48 h, the infected cells were harvested with Accutase (StemCell Technologies Inc., Vancouver, Canada) for flow-cytometry analysis. To analyze the surface expression level of CXCR4 and CX3CR1, the MSCs were harvested with Accutase (StemCell Technologies Inc.) and incubated with control rabbit IgG (eBioscience, San Diego, CA, USA), or polyclonal antibodies against human CXCR4 (1:50; Novus Biologicals, Littleton, CO, USA) and CX3CR1 (1:100; Abcam, Cambridge, UK) at 4 1Cfor 1 h. After the PBS wash, the cells were incubated with phycoerythrin-conjugated, goat anti-rabbit IgG at 4 1Cfor 30 min. The samples were then analyzed on a Becton Dickinson FACSCalibur flow cytometer (San Jose, CA, USA), and data analysis was performed using BD CellQuest Pro software version 4.0.2.
In vitro migration assay HT29 human colon cancer cell line, MCF7 human breast cancer cell line, A549 human lung adenocarcinoma epithelial cell line and minced solid colon cancer tissue were plated onto 24-well plates in their growth medium 24 h before the migration assay was performed. Hypoxia or normoxic MSCs were seeded onto the 8-mm pore-size cell-culture inserts (Corning, New York, NY, USA), at 3000 cells per well, and allowed to adhere for 1 h at 37 1C. The inserts were then added to the wells and incubated at 37 1C, with 5% CO 2 . To block the activity of CXCR4, the MSCs were incubated with NAb against CXCR4 (10 mg ml À 1 ; R&D System, Minneapolis, MN, USA) for 30 min, before loading onto the insert. To block the activity of CX3CL1/fractalkine, NAb against CX3CL1 (15 mg ml À 1 ; R&D System) was added into the medium in the lower chamber for 30 min, before the transwell chamber was assembled. After 14 h of migration, the medium was removed, and cells that remained attached to the upper surface of the insert filters were removed, using cotton swabs. The cells that had migrated to the lower surface of the filters were stained with 4',6-diamidino-2-phenylindole and counted under a fluorescent microscope. The average number of migrating cells per field was assessed by counting four random fields per filter.
Cytotoxicity assay
To determine the CRAd-mediated cytotoxicity, the MSCs and HT29 cells were plated in a 24-well plate, at 5 Â 10 4 and 2 Â 10 6 cells per well, respectively, and infected with CRAd-EGFP at different MOI (0, 10, 100 or 1000). The cells were incubated at 37 1C for 3 and 7 days. To determine the cytotoxicity of the MSC-delivered CRAds, hypoxic MSCs were infected with CRAd-EGFP at an MOI of 1000 for 48 h before direct coculture with HT29 cells, in a ratio of 1:10 in the absence or presence of 50 ml high-titer human serum diluted in 2 ml Dulbecco's modified Eagle medium per well of a sixwell plate. The mixed culture cells were incubated at 37 1C for 7 days. A 3(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide assay and crystal violet staining were performed to measure and visualize the cytolysis level. At different times during the culture, the medium was removed, the cells were washed once with PBS and 900 ml of medium and 100 ml of 3(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide solution (5 mg ml À 1 ) were added into each well and incubated at 37 1C for 4 h. At the end of incubation, the medium was aspirated and 200 ml of DMSO was added to dissolve the dye. The absorbance at O.D. 570 was measured, using a Tecan microplate reader (Infinite M1000; Tecan, San Jose, CA, USA). The results are shown as the mean of three independent wells ±s.e. The control wells without cells were used to account for the colorant retained by the culture plates. For crystal violet staining, the cells were fixed with 10% buffered formalin for 5 min and stained with 1% crystal violet, at room temperature for 20 min. Images of the plates were then captured with a scanner. The 3(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide assay and the crystal violet were performed in parallel.
Western blotting
Cell extracts were prepared with Mammalian Protein Extraction Reagent (Pierce, Rockford, IL, USA), containing protease inhibitor cocktail (Halt; Pierce), and protein concentrations were determined using a Coomassie (Bradford) Protein Assay Kit (Thermo Scientific, Rockland, IL, USA). Thirty microgram of protein lysates were separated on SDS-10% polyacrylamide gels and transferred onto polyvinylidene fluoride membranes (Millipore, Marlborough, MA, USA). After transfer, the membranes were incubated in a buffer containing 0.1% tween-20 and 5% nonfat milk, for 1 h at room temperature, and then reacted sequentially with primary and secondary antibodies in a similar buffer. The primary antibodies used in this work were anti-CXCR4 antibody (1:5000; Novus Biologicals), anti-CX3CR1 antibody (1:1000; Abcam), anti-HIF-1a antibody (1:1000; GeneTex, San Antonio, TX, USA) and anti-Actin antibody (1:5000; eBioscience). Horseradish peroxidase-conjugated secondary anti-mouse and anti-rabbit IgG (GE HealthCare, Uppsale, Sweden) were used at a 1:5000 dilution. The antigen-antibody complexes were visualized using enhanced chemiluminescence detection reagents (PerkinElmer Life and Analytical Science, Shelton, CT, USA) according to the manufacturer's protocols.
Virus replication
MSCs and HT29 cells were plated on 10-cm plates, at 2 Â 10 5 and 1 Â 10 6 , respectively, and infected with CRAd-EGFPs at 1 Â 10 8 vp per plate. After 2 h of infection, the medium was replaced with fresh culture medium and cells were harvested for DNA extraction, at 2, 24, 48, 72 and 96 h after infection, using a DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA, USA). The concentration of adenovirus DNA was determined by quantitative PCR (qPCR), using the ABI Applied Biosystems (Foster City, CA, USA) with StepOne software v2.0. Amplification was performed in a total volume of 20 ml, with SYBR Green PCR MasterMix (Applied Biosystems), the extracted DNA and forward (5 0 -CTTCGATGATGCCGCAGTG-3 0 ) and reverse (5 0 -GGGCTCAGGTACTCCGAGG-3 0 ) hexon primers. The reaction conditions were one cycle at 95 1C for 10 min, then 40 cycles each at 95 1C for 15 s, 56 1C for 15 s and 72 1C for 40 s. The amount of adenovirus was quantified using a standard curve created from the serial dilutions of the adenovirus stock, from 3 Â 10 7 to 30 viral particles, in a background of human genomic DNA. The samples were amplified in duplicate, and the mean total virus number was normalized to total DNA (mg DNA) À 1 .
NAb assay
Human sera were provided by the blood bank of Taipei Veterans General Hospital. The protocol for the determination of the titer of the adenovirus NAb in sera is based on that published by Rahman and colleagues 11 . In brief, HT29 cells were plated in a 96-well plate at 1 Â 10 4 cells per well, on the day before the analysis. A set of serial 1/2 dilutions was made, starting at 1:10. The appropriately diluted serum samples were incubated with equal volumes of CRAd-EGFP (2 Â 10 6 vp), containing Dulbecco's modified Eagle medium, at 37 1C for 30 min. At the end of the incubation, the medium form HT29 cell cultures were removed, and 100 ml of the diluted serum plus CRAd-EGFP was added into each well. After 48 h of incubation, the intensity of the fluorescence was detected, and the relative fluorescence was measured to assay the neutralizing capacity. The background was assessed in the wells containing HT29 cells alone, and the CRAd-EGFP fluorescence was assessed in wells containing cells and CRAd-EGFP in the absence of human serum.
Human xenograft HT29 colon cancer model All procedures involving animals were reviewed and approved by the animal center committee of the Veterans General Hospital, Taipei. To establish peritoneal colon cancer mice models, 8-week-old male athymic Balb/c mice were i.p. injected with 5 Â 10 6 HT29 cells. After 7 days, the mice were randomly divided into three groups of five mice each and i.p.
injected once with 1 Â 10 6 control MSCs (MSC/CTR), CRAd-EGFP-loaded MSCs (MSC/CRAd-EGFP), or 1 Â 10 9 CRAd-EGFP suspended in the 1:10 diluted NAb-containing human serum (50 ml serum in 500 ml PBS). To establish subcutaneous colon cancer mice models, 8-week-old male athymic Balb/c mice were s.c. inoculated with 1 Â 10 6 HT29 cells. After 3 days of inoculation, they were randomly divided into three groups of five mice each and intravenously (i.v.) injected once with 1 Â 10 6 control MSCs (MSC/CTR), CRAd-EGFP-loaded MSCs (MSC/CRAd-EGFP) or 1 Â 10 9 CRAd-EGFP suspended in the 1:10 diluted NAb-containing human serum (10 ml serum in 100 ml PBS). Tumors from all groups of mice were measured every week after treatment. After 5 weeks of treatment, the tumors were harvested for immunostaining with anti-GFP, anti-CDX2 and anti-CD44 antibodies.
Statistical analysis
All values are expressed as mean ± s.e. Comparisons between two groups were analyzed using a Student's t-test. A value of Po0.05 is considered to be statistically significant.
RESULTS
Hypoxic culture increases the migration of MSCs to cancer cells via the upregulation of CXCR4 and CX3CR1 expression As only a small portion of the MSCs that were systemically administered could reach the tumor sites, 32, 33 the identification of MSCs with superior tumor tropism is most important for the use of MSCs as carriers to send an oncolytic virus to the tumor. To determine whether the tumor tropism of the MSCs is altered by hypoxic culture, the in vitro migration capabilities toward cancer cells for MSC culture under hypoxic and normoxic conditions were compared. Although both the hypoxic and normoxic MSCs demonstrated increased migration to human cancer cells, including HT29, MCF7, A549 and minced solid tumor tissue, the increase for hypoxic MSCs was significantly greater than that for normoxic MSCs (Figure 1a) . Because chemokine receptors, such as CXCR4 and CX3CR1, are important in mediating the migration of MSCs to bone marrow and damaged tissues, 34, 35 it was then determined whether the increased tumor-homing ability of hypoxic MSCs can be attributed to the upregulation of these chemokine receptors. Similarly to a previous report, 29 flow cytometry (Figure 1b) and western blot analysis (Figure 1c ) revealed that the hypoxic culture increases the surface expression of CXCR4 and CX3CR1. More importantly, enzyme-linked immunosorbent assay analysis further demonstrates that HT29 release their ligands, SDF-1a and CX3CL1, in the medium (Figure 1d ). As expected, blocking the chemokine receptor with NAbs against CXCR4 and CX3CL1 inhibits the migration of hypoxic MSCs to tumor sites (Figure 1e ). These data together suggest that hypoxic culture increases the migration of MSCs to cancer cells, via increased CXCR4 and CX3CR1 expression.
Hypoxic MSCs are successfully transduced by CRAds and support adenoviral replication As an adenovirus carrier, MSCs must be successfully infected by CRAds. To assess the infection efficiency of CRAds on MSCs, hypoxic and normoxic MSCs were infected with CRAd-EGFP, followed by flow cytometry, 48 h later, to quantify the EGFP þ cells. The result shows that approximately 74% of both hypoxic and normoxic MSCs express EGFP and that CRAd infects normoxic and hypoxic MSCs with equal efficiency (Figure 2a) . Because a hypoxic culture of MSCs not only enhances tumor tropism but also allows more expansion than a normoxic culture, as previously demonstrated, [25] [26] [27] [28] [29] the suitability of hypoxic MSCs as a vehicle to carry CRAds was then determined.
Besides carrying cargo to target sites, cellular carriers should also possess the ability to amplify oncolytic virus and deliver more than that was actually packed. 36 However, this strategy seems to present an intrinsic contradiction. Because a rapid amplification of oncolytic viruses would lead to lytic effects on the carriers, identification of cellular carriers with a slow but steady viral replication rate is a prerequisite to achieve this aim. Therefore, we analyzed the adenoviral DNA content in infected hypoxic MSCs at different time points using qPCR. The sensitivity of detection and the linear range of the qPCR were determined by serial dilution of the CRAd-EGFP virus stock, from 10 7 to 10 1 . The standard curve has a slope of À 3.663, and the correlation coefficient between the virus number and the threshold cycle value is 0.996 (Figure 2b) . The DNA extracts of the MSCs were used as templates for qPCR, and the virus replication reached a peak at 72 h (approximately 2.5 Â 10 7 virus particles per mg DNA) (Figure 2c ), suggesting a continuous replication of virus before this time point. However, the rate of replication in hypoxic MSCs was lower than that in HT29 tumor cells (Figure 3a) . These results suggest that hypoxic cultured MSCs are suitable as cell carriers for CRAds.
High CRAd-replication rates and the cytolytic effect in colon cancer cells Virus replication in tumor cells is critical for the initiation of tumor lysis induced by viruses and is also important for the subsequent spread of viruses to other tumor cells, so the adenoviral DNA content in infected HT29 cells at different time points was also quantified using qPCR. The result showed that the replication of CRAds in HT29 reached a peak at 48 h (approximately 5.3 Â 10 7 virus particles per mg DNA) (Figure 3a) , which was higher than that in MSCs (Figure 2c ). The degree of the cytolytic effect of CRAds on the virus carrier and the tumor cells was then determined. Hypoxic MSCs and HT29 cells were infected with CRAd-EGFP at different values of MOI, and cell viability was determined using crystal violet staining and a 3(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide assay. On day 3, most MSCs remained alive at each tested MOI, whereas 40% and 470% of HT29 cells exhibit cell lysis at an MOI of 100 and 1000, respectively. MSCs began to show cell lysis at an MOI of 1000 7 days post infection, at which time HT29 cells exhibit complete lysis, at MOI of both 100 and 1000 (Figures 3b  and c) . These results indicate that CRAds prefer to replicate within and lyse HT29 human colon cancer, rather than MSCs.
MSCs protect CRAds from anti-adenovirus NAbs and deliver these viruses to colon cancer cells in vitro
The adaptive immune system presents a serious obstacle to the systemic administration of adenovirus in clinical patients, given that the majority of the human population has been infected by adenovirus and has developed an adaptive immunity, such as humoral immunity. 37 To determine whether hypoxic MSCs protect CRAds from attack by preexisting NAbs and carry them to tumor Figure 2 . CRAds expressed and replicated in hypoxic MSCs. (a) The CRAds infection efficiency of hypoxic and normoxic MSCs was determined using flow cytometry. MSCs were infected with CRAd-EGFP for 48 h, and then cells were harvested for flow-cytometry analysis using GFP marker. The cells without infection were used as control (CTR). Three independent experiments were performed, and one representative result was shown. (b) Standard curve generated by qPCR. The DNA of CRAds was extracted from serially diluted CRAd-EGFP stock (10 7 -10 1 viral particles), and used as a template for qPCR. Threshold cycle (Ct) values were plotted against adenovirus particle number. (c) CRAd-infected hypoxic MSCs were harvested at different time intervals of 2, 24, 48, 72 and 96 h post infection and were subjected to extraction of viral DNA followed by qPCR. CRAd particle number was calculated based on the standard curve. Two independent experiments were performed, and one representative result was shown.
cells, CRAd-EGFP-loaded MSCs were cocultured with HT29 cells at a ratio of 1:10 in the absence or presence of NAbs. Human sera with a high NAb titer, ID50 4320, 11 was used in the studies. After 48 h of coculture, the MSCs successfully protect and deliver CRAd-EGFP to tumor cells, which began to express EGFP (Figures 4a and b) , while loading with CRAd-EGFP alone failed to target tumor cells. The tumor-lysis effect of CRAd-EGFP in the absence and presence of NAbs was then compared in vitro. After 7 days of loading to tumor cells, both cell-free and MSC-carrying CRAd-EGFP cause significant tumor cell lysis in the absence of NAbs, whereas CRAd-EGFP carried by MSCs, rather than free CRAd-EGFP, induces tumor cell lysis in the presence of NAbs (Figures 4c  and d) . These data together suggest that MSCs are suitable as a CRAd carrier, protect the cargo on the journey to the tumor and induce tumor lysis in vitro.
CRAd-loaded MSCs are attracted to intraperitoneal and subcutaneous xenografts of human colon cancer To determine whether CRAd-loaded MSCs can migrate and deliver viruses to tumor cells in the presence of NAbs in vivo, two mice xenograft models were established. In the first model, athymic mice with pre-established peritoneal HT29 xenografts were i.p. injected with cell-free or MSC-carrying CRAd-EGFP in the presence of NAbs. After 5 weeks of treatment, human colon cancer xenografts were harvested for immunofluorescence staining, to assess the expression of GFP and the colon cancer marker, CDX2. Abundant CDX2 signal was discovered for all of the treatment types, but only tumors from mice injected with MSC-carrying CRAd-EGFP express GFP with colocalized CDX2 immunostaining (Figure 5a ). To determine whether circulatory CRAd-loaded MSCs can target microscopic tumors, a second group of mice was used. Athymic mice were s.c. inoculated with HT29 cells. Three days after inoculation, these mice were i.v. injected with cell-free or MSC-carrying CRAd-EGFP in the presence of NAbs. Tumor volumes were measured every week during the treatment period of 5 weeks. At the end of the treatment, tumor xenografts were harvested for immunofluorescence staining, to assess the expression of EGFP and the colon cancer marker, CDX2. The results show that although the average tumor volume for the MSC-carrying CRAd-EGFP remains similar to that for the mice injected with free CRAd-EGFP or with MSCs not carrying CRAd-EGFP (Figure 5b ), only tumors from the mice injected with MSC-carrying CRAd-EGFP express GFP with colocalized CDX2 immunostaining (Figure 5c ). Because the GFP fluorescence signals are not colocalized by CD44 immunostaining (Figures 5d and e) , the GFP-expressing cells are not MSCs. These results together suggest that MSC-carrying CRAd-EGFPs are resistant to attack by existing NAbs and deliver CRAds to their target tumor cells, both in vitro and in vivo. These data suggest that although CRAd-EGFPs carried by MSCs are not powerful enough to lyse tumor cells, under the protection of MSCs, these viruses escape from attack by NAbs.
DISCUSSION
Although early clinical trials with oncolytic adenoviruses have demonstrated good safety, the limited efficacy of oncolytic virus therapy has been noted because of the preexisting serum factors, such as NAbs in hosts. This study finds that MSCs cultured under hypoxic conditions cause an increase in the surface levels of chemokine receptors, such as CXCR4 and CX3CR1, thereby increasing their migration toward tumor sites. In addition, the ability of the MSCs to package CRAds is not altered by hypoxic culture, and CRAds can replicate in these cells. Furthermore, in the presence of NAbs, hypoxic MSCs successfully deliver CRAds to HT29 cancer cells, causing virus replication and subsequent oncolysis in cancer cells. In vivo studies further confirm the delivery of CRAds to i.p. and s.c established xenograft tumors in immuno-deficient mice by i.p. and i.v. injected MSCs, respectively. Taken together, these data suggest that hypoxic cultured MSCs are suitable carriers for CRAds.
MSCs are immune-privileged and can serve as immune modulators, so MSCs can be used in immune-competent allogeneic recipients. 38 Thus, MSCs derived from a single healthy donor may be used as oncolytic virus carriers in many patients, Figure 3 . CRAds replicated and induced cytolytic effect in colon cancer cells. (a) CRAd-infected HT29 cells were harvested at different time intervals of 2, 24, 48, 72 and 96 h post infection and were subjected to extraction of viral DNA followed by qPCR. CRAd particle number was calculated based on the standard curve. Two independent experiments were performed, and one representative result was shown. Hypoxic MSCs and HT29 cells were infected with CRAd-EGFP at indicated MOI. After (b) 3 and (c) 7 days of infection, cells were fixed and stained with crystal violet, or subjected to 3(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide assay. The images shown here are representatives of three independent experiments. Each bar represents the mean ± s.e. of three independent experiments. *Po0.05 compared with uninfected cells.
which shortens the preparation process. However, long-term expansion, in vitro, induces replication senescence 39, 40 and alters the proliferation capacity, the differentiation potential and the migration activity. 41, 42 Hypoxic culture has been reported to prevent proliferation senescence, increase proliferation capacity and maintain the differentiation potential of MSCs. 25 This study demonstrates that hypoxic MSCs not only increase the ability to target tumors, compared with normoxic MSCs but are also suitable for the delivery of CRAds.
Although the use of MSCs as an oncolytic virus carrier for tumor targeting, in vivo, has been in the subject of previous studies, [19] [20] [21] [22] 43 most of these studies either neglected the influence of NAbs or used questionable animal models. Following intratumoral injections, oncolytic viruses fail to efficiently migrate away from the injection site and are rapidly cleared by the immune system. Using the semipermissive cotton rat model, Ahmed et al. 22 demonstrated that cotton rat MSCs, following intratumoral injections, enhanced the dissemination and persistence of Ad, compared with virus injection alone. Mader et al. 20 showed that i.p. injected MSCs protect oncolytic measle viruses from antibody neutralization in human orthotopic ovarian cancer xenograft models. However, intravenous injection is the proper delivery route for the targeting of both primary and undiagnosed metastatic tumors and can be easily performed in a clinical setting. 11, 44 In this regard, this study demonstrated that i.v. and i.p. injected hypoxic MSCs target and deliver CRAd-EGFP to microscopic subcutaneous and intraperitoneal xenograft colorectal tumors, in the presence of NAbs.
Although MSCs deliver CRAds to tumor cells, the size of the tumors in the CRAd-EGFP-loaded MSC-treated mice are not suppressed, compared with control MSC-treated mice. Several factors may contribute to this major limitation. First, MSCs express low levels of surface CAR and are relatively resistant to adenovirus infection. 45 Second, the CRAds used in this study were constructed with the deletion of E1B-55KD, an important component for viral replication and production, so the ability to lyse tumors was reduced. 46 For example, clinical studies have shown that H101, an oncolytic adenovirus with E1B-55KD and partial E1A deletion, has good efficacy only when combined with chemotherapy. 47 Third, when admixed with tumor cells, MSCs enhance the initiation of colorectal tumors and the angiogenesis and growth of tumors via the secretion of cytokines, such as IL-6. 48, 49 There are several means of overcoming these obstacles. Histone deacetylase inhibitors, such as trichostatin A, have been reported to upregulate CAR expression in cancer cells. 50 The gene-directed enzyme-prodrug approach, which increases anticancer efficacy via the localized conversion of nontoxic prodrug to active cytotoxic derivatives using enzymes within the tumor, 51, 52 can be used to improve tumor lysis. MSCs can also act as more than an oncolytic virus carrier. For example, MSCs are activated by recombinant human tumor necrosis factor-a to express a tumor necrosis factor-a-related apoptosis-inducing ligand that demonstrates cancer apoptotic activity. 53 In conclusion, this study demonstrates that hypoxic MSCs increase the expression of chemokine receptors and the ability to migrate and target tumor sites. They are also suitable for the packaging, protection and delivery of CRAds to target tumor cells, in the presence of NAbs. These methods, using hypoxic MSCs as carriers for CRAds, allow strategies for the treatment of cancers. Figure 5 . CRAd-loaded MSCs homed to intraperitoneal and subcutaneous xenografts of human colon cancer. (a) The fluorescence microscopy images of HT29 peritoneal tumor sections. The GFP (green) and CDX2 (red) expressions of peritoneal tumor sections from different groups of mice were determined using immunofluorescence co-staining with specific antibodies. Nuclei were counterstained with 4' ,6-diamidino-2-phenylindole (DAPI) (blue). (b) Mean subcutaneous tumor volume ( ± s.e.) for three male athymic mice over 5 weeks from treatment. (c) The fluorescence microscopy images of HT29 subcutaneous tumor sections. The GFP (green) and CDX2 (red) expressions of subcutaneous tumor sections from different groups of mice were determined using immunofluorescence co-staining with specific antibodies. Nuclei were counter stained with DAPI (blue). (d) The GFP (green) and CD44 (red) expression of peritoneal and (e) subcutaneous tumor sections from different groups of mice was determined using immunofluorescence co-staining with specific antibodies. Nuclei were counterstained with DAPI (blue). All the scale bars represent 100 mm.
